- Home
- STAI vs ELEV Comparison
STAI vs ELEV Comparison
Compare STAI & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- ELEV
- Stock Information
- Founded
- STAI 2011
- ELEV 2019
- Country
- STAI United States
- ELEV United States
- Employees
- STAI N/A
- ELEV 34
- Industry
- STAI
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- ELEV Health Care
- Exchange
- STAI Nasdaq
- ELEV Nasdaq
- Market Cap
- STAI 20.2M
- ELEV 22.8M
- IPO Year
- STAI N/A
- ELEV 2021
- Fundamental
- Price
- STAI $0.73
- ELEV $0.38
- Analyst Decision
- STAI
- ELEV Hold
- Analyst Count
- STAI 0
- ELEV 6
- Target Price
- STAI N/A
- ELEV $1.77
- AVG Volume (30 Days)
- STAI 776.7K
- ELEV 2.0M
- Earning Date
- STAI 01-01-0001
- ELEV 08-05-2025
- Dividend Yield
- STAI N/A
- ELEV N/A
- EPS Growth
- STAI N/A
- ELEV N/A
- EPS
- STAI N/A
- ELEV N/A
- Revenue
- STAI $542,166.00
- ELEV N/A
- Revenue This Year
- STAI N/A
- ELEV N/A
- Revenue Next Year
- STAI N/A
- ELEV N/A
- P/E Ratio
- STAI N/A
- ELEV N/A
- Revenue Growth
- STAI N/A
- ELEV N/A
- 52 Week Low
- STAI $0.66
- ELEV $0.22
- 52 Week High
- STAI $9.07
- ELEV $3.28
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- ELEV 61.76
- Support Level
- STAI N/A
- ELEV $0.38
- Resistance Level
- STAI N/A
- ELEV $0.39
- Average True Range (ATR)
- STAI 0.00
- ELEV 0.01
- MACD
- STAI 0.00
- ELEV 0.01
- Stochastic Oscillator
- STAI 0.00
- ELEV 82.08
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.